Lingdi Ma

432 total citations
25 papers, 363 citations indexed

About

Lingdi Ma is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Lingdi Ma has authored 25 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 10 papers in Immunology and 6 papers in Oncology. Recurrent topics in Lingdi Ma's work include Immune Cell Function and Interaction (9 papers), Bioactive natural compounds (7 papers) and Bioactive Compounds and Antitumor Agents (5 papers). Lingdi Ma is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Bioactive natural compounds (7 papers) and Bioactive Compounds and Antitumor Agents (5 papers). Lingdi Ma collaborates with scholars based in China, Sweden and Bangladesh. Lingdi Ma's co-authors include Jikai Jiang, Shihong Wen, Xiaoshan Liu, Yujuan He, Yan Zhan, Xuzhang Lu, Zhichao Zhu, Xiao Sun, Min Zhou and Sixuan Qian and has published in prestigious journals such as Oncotarget, Frontiers in Pharmacology and Molecular and Cellular Endocrinology.

In The Last Decade

Lingdi Ma

25 papers receiving 350 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lingdi Ma China 11 240 68 65 44 40 25 363
Hidetomo Kikuchi Japan 12 372 1.6× 117 1.7× 51 0.8× 53 1.2× 46 1.1× 22 552
Alessia Petronelli Italy 6 349 1.5× 56 0.8× 48 0.7× 30 0.7× 47 1.2× 8 446
Ashley Boice United States 3 279 1.2× 47 0.7× 48 0.7× 27 0.6× 45 1.1× 7 397
Hanchi Miao China 7 234 1.0× 48 0.7× 49 0.8× 63 1.4× 39 1.0× 7 345
Lena Schultz United States 11 363 1.5× 61 0.9× 50 0.8× 99 2.3× 45 1.1× 18 617
Young-Hee Kang South Korea 7 279 1.2× 64 0.9× 37 0.6× 23 0.5× 31 0.8× 9 416
Zhonghuang Li China 15 288 1.2× 101 1.5× 40 0.6× 33 0.8× 24 0.6× 32 508
Nikhil Vad United States 10 246 1.0× 72 1.1× 29 0.4× 50 1.1× 56 1.4× 14 420
Gauri Deb United States 10 357 1.5× 80 1.2× 41 0.6× 29 0.7× 98 2.5× 18 542
Wanzhou Zhao China 12 296 1.2× 73 1.1× 63 1.0× 108 2.5× 54 1.4× 21 481

Countries citing papers authored by Lingdi Ma

Since Specialization
Citations

This map shows the geographic impact of Lingdi Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingdi Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingdi Ma more than expected).

Fields of papers citing papers by Lingdi Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingdi Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingdi Ma. The network helps show where Lingdi Ma may publish in the future.

Co-authorship network of co-authors of Lingdi Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Lingdi Ma. A scholar is included among the top collaborators of Lingdi Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingdi Ma. Lingdi Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ma, Lingdi, et al.. (2022). Matrine, a potential c-Myc inhibitor, suppresses ribosome biogenesis and nucleotide metabolism in myeloid leukemia. Frontiers in Pharmacology. 13. 1027441–1027441. 4 indexed citations
2.
Ma, Lingdi, et al.. (2020). Morinda citrifolia (Noni) Juice Suppresses A549 Human Lung Cancer Cells via Inhibiting AKT/Nuclear Factor-κ B Signaling Pathway. Chinese Journal of Integrative Medicine. 27(9). 688–695. 11 indexed citations
3.
Wu, Yangzhe, et al.. (2019). Matrine Promotes Human Myeloid Leukemia Cells Apoptosis Through Warburg Effect Mediated by Hexokinase 2. Frontiers in Pharmacology. 10. 1069–1069. 30 indexed citations
4.
Cai, Xiaohui, Xuzhang Lu, Xiuwen Zhang, et al.. (2015). STAT3 contributes to NK cell recognition by modulating expression of NKG2D ligands in adriamycin-resistant K562/AO2 cells. International Journal of Hematology. 102(5). 536–543. 8 indexed citations
5.
6.
Zhu, Zhichao, Xuzhang Lu, Xiao Sun, et al.. (2015). STAT3 signaling pathway is involved in decitabine induced biological phenotype regulation of acute myeloid leukemia cells.. PubMed. 7(10). 1896–907. 16 indexed citations
7.
Ma, Lingdi, Zhichao Zhu, Xuzhang Lu, et al.. (2014). [Up-regulation of NKG2D ligand ULBP2 by matrine in K562 cells and the underlying molecular mechanisms].. PubMed. 35(5). 438–42. 3 indexed citations
8.
Ma, Lingdi, Xuzhang Lu, Zhichao Zhu, et al.. (2013). [Effects of matrine on the expression of NKG2D ligands in leukemia cells].. PubMed. 21(6). 1429–34. 1 indexed citations
9.
He, Jinyuan, Xiaohui Cai, Rong Xiao, et al.. (2013). [Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines].. PubMed. 21(6). 1380–4. 5 indexed citations
10.
Lu, Xuzhang, Xiaohui Cai, Lingdi Ma, et al.. (2012). Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells. Cancer Biology & Therapy. 13(8). 623–629. 16 indexed citations
11.
Li, Fei, Ruixia Zhu, Zhongxin Zhou, et al.. (2011). Heme oxygenase-1 is induced by thyroid hormone and involved in thyroid hormone preconditioning-induced protection against renal warm ischemia in rat. Molecular and Cellular Endocrinology. 339(1-2). 54–62. 21 indexed citations
12.
Ma, Lingdi, et al.. (2010). Matrine: A novel inhibitor of growth and proliferation of lung adenocarcinoma cells. Journal of Medicinal Plants Research. 4(5). 375–386. 3 indexed citations
13.
Ma, Lingdi, et al.. (2010). Effects of STAT3 silencing on fate of chronic myelogenous leukemia K562 cells. Leukemia & lymphoma. 51(7). 1326–1336. 15 indexed citations
14.
Wang, Yong, Lingdi Ma, Shizhong Wang, et al.. (2009). Assessment of CAR- or CD46-Dependent Adenoviral Vector-Mediated TRAIL Gene Therapy in Clinical Adenocarcinoma Lung Cancer Cells. Oncology. 77(6). 366–377. 6 indexed citations
15.
Liu, Qian, Lingdi Ma, & Yong Wang. (2009). [Research Advance of TRAIL Molecular Target in the Therapy of Lung Cancer.].. PubMed. 12(3). 252–5. 1 indexed citations
16.
Wang, Yong, et al.. (2009). Expression of coxsackie and adenovirus receptor in small cell lung cancer. The Chinese-German Journal of Clinical Oncology. 8(9). 504–505. 2 indexed citations
17.
Ma, Lingdi, Shihong Wen, Yan Zhan, et al.. (2008). Anticancer Effects of the Chinese Medicine Matrine on Murine Hepatocellular Carcinoma Cells. Planta Medica. 74(3). 245–251. 127 indexed citations
18.
Ma, Lingdi, Yan Zhang, Shihong Wen, et al.. (2008). [Enhancing effect of matrine on the tumor-inhibition by TIM2 gene-modified hepatocarcinoma H22 cells in mice].. PubMed. 30(4). 255–8. 2 indexed citations
19.
Ma, Lingdi, Yan Zhang, Shihong Wen, et al.. (2008). [Effects of matrine on oncogenicity of H22 cells modified by TIM2 gene in vivo].. PubMed. 33(10). 1175–9. 1 indexed citations
20.
Ma, Lingdi, Yan Zhang, Shihong Wen, et al.. (2005). [Inhibition of tumor growth in tumor-bearing mice treated with matrine].. PubMed. 27(6). 339–41. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hidetomo Kikuchi Breakdown of academic impact, for papers by Alessia Petronelli Breakdown of academic impact, for papers by Ashley Boice Breakdown of academic impact, for papers by Hanchi Miao Breakdown of academic impact, for papers by Lena Schultz Breakdown of academic impact, for papers by Young-Hee Kang Breakdown of academic impact, for papers by Zhonghuang Li Breakdown of academic impact, for papers by Nikhil Vad Breakdown of academic impact, for papers by Gauri Deb Breakdown of academic impact, for papers by Wanzhou Zhao
Rankless by CCL
2026